Interestingly, the in silico binding activity of globospiramine (1) to MAPK14 may also explain its relatively weaker in vitro cytotoxicity against triple-negative breast cancer cell lines, especially MDA-MB-231. The gene discussed is MAPK14; the disease is triple-negative breast carcinoma.